Manchester spin-out Imperagen raises $6.4M to engineer enzymes 500x faster
What's the deal? Imperagen, a University of Manchester spin-out, has raised £5M ($6.4M) in seed funding to commercialise its platform that combines AI with quantum physics to engineer enzymes up to 500 times faster than traditional methods.
The company's technology models quantum mechanical effects — such as quantum tunnelling — that govern how enzymes catalyse reactions. By integrating these physics-based models with machine learning, Imperagen says it can predict enzyme behaviour with far greater accuracy than conventional approaches, which often rely on trial and error.
Why now? Enzymes are increasingly central to industries ranging from pharmaceuticals to biofuels and food production, but engineering them remains slow and expensive. Traditional directed evolution methods can take years to optimise a single enzyme. Imperagen argues its computational approach can compress that timeline dramatically, arriving at better-performing enzymes in a fraction of the time.
The growing demand for sustainable manufacturing processes — where enzymes replace harsh chemical catalysts — has also created urgency. Companies across sectors are looking for greener, more efficient production methods, and faster enzyme design could unlock significant commercial opportunities.
What could go wrong? Translating academic breakthroughs in quantum biology into reliable, scalable commercial products is no small feat. The science underpinning Imperagen's platform is cutting-edge, which means it is also largely unproven at industrial scale. Convincing large enterprise customers to trust a novel computational approach over established wet-lab methods could take time.
Competition in the AI-driven protein and enzyme engineering space is also intensifying, with well-funded players and big tech companies investing heavily in the area.
The signal: Imperagen's seed round underscores rising investor conviction in deep-tech platforms that merge AI with hard science to tackle bottlenecks in biologics and green chemistry. The company's early growth classification on Dealroom suggests it is already moving beyond pure research toward commercial traction — a meaningful milestone for a university spin-out operating in a space where the gap between lab promise and industrial adoption remains wide.
Read more: Tech Funding News
